Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
06 Septiembre 2024 - 6:00AM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that Gwenn M. Hansen, Ph.D., chief
scientific officer of Nurix, will present an update on Nurix’s
Degrader-Antibody Conjugate (DAC) platform at the ADC &
Radiopharmaceuticals Pharma & Biotech Partnering Summit being
held in Boston from September 9-10, 2024.
Title: Targeted Protein Degraders As Next Generation Antibody
Payloads Conference: ADC & Radiopharmaceuticals Pharma &
Biotech Partnering SummitDate and time: Tuesday, September 10, 9:05
– 9:25 a.m. ET
The slides for this presentation may be accessed beginning on
September 9, 2024, via a link in the Investors section of the Nurix
website under Events and Presentations.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
Media
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Nurix Therapeutics (NASDAQ:NRIX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024